Sarpogrelate, a 5-hydroxytryptamine type 2A antagonist, is a potential antiplatelet agent. We performed a randomized study to evaluate the effect of sarpogrelate on vascular health in Korean patients with diabetes.Forty diabetic patients aged 58.6 ± 6.8 years with 10-75
作者：Dong-Hwa, Lee；Eun Ju, Chun；Jee Hye, Hur；Se Hee, Min；Jie-Eun, Lee；Tae Jung, Oh；Kyoung Min, Kim；Hak Chul, Jang；Seung Jin, Han；Doo Kyoung, Kang；Hae Jin, Kim；Soo, Lim
来源：Atherosclerosis 2017 年 257卷
